Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Asset disposition
Director departure
Quarterly results
Auditor change
Acq. announced
Consulting agrmnt
Appointed director
Inv. presentation
LISATA THERAPEUTICS, INC. (CLBS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update",
"2 0 2 3 L"
07/13/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update",
"2 0 2 3 L"
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/06/2023 8-K Quarterly results
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/12/2023 4 Mazzo David J (CEO) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 1,030 shares @ $3.2, valued at $3.3k
01/11/2023 4 Ruoslahti Erkki (Director) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 20,000 shares @ $0
01/11/2023 4 KLOSK STEVEN M (Director) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 20,000 shares @ $0
01/11/2023 4 HENSON HEIDI (Director) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 20,000 shares @ $0
01/11/2023 4 Flowers Cynthia Louise (Director) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 20,000 shares @ $0
01/11/2023 4 BROWN GREGORY B (Director) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 20,000 shares @ $0
01/11/2023 4 AZAB MOHAMMAD (Director) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 20,000 shares @ $0
01/11/2023 4 Slack David W. (President & CBO) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 24,000 shares @ $0
Paid exercise price by delivering 3,358 shares @ $3, valued at $10.1k
Granted 12,000 options to buy @ $3, valued at $36k
01/11/2023 4 Mazzo David J (CEO) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 60,000 shares @ $0
Paid exercise price by delivering 7,845 shares @ $3, valued at $23.5k
Paid exercise price by delivering 3,470 shares @ $3.195, valued at $11.1k
Granted 30,000 options to buy @ $3, valued at $90k
01/11/2023 4 Buck Kristen K (EVP, R&D and CMO) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 18,000 shares @ $0
Paid exercise price by delivering 2,147 shares @ $3, valued at $6.4k
Paid exercise price by delivering 512 shares @ $3.195, valued at $1.6k
Granted 9,000 options to buy @ $3, valued at $27k
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
10/14/2022 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Withum Smith+Brown, PC, independent registered public accounting firm"
10/04/2022 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "“Cend Business” section excerpt from Registration Statement",
"“Risk Factors” section excerpt from Registration Statement",
"Unaudited condensed interim financial statements of Cend as of June 30, 2022 and for the six months ended June 30, 2022 and 2021",
"Unaudited pro forma condensed combined financial information of the Company as of June 30, 2022 and for the six months ended June 30, 2022"
09/29/2022 8-K Quarterly results
09/26/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/22/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "NOVEL INTRATUMORAL DELIVERY TECHNOLOGY TO IMPROVE THERAPEUTIC EFFICACY OF"
09/16/2022 3 Slack David W. (President & CBO) has filed a Form 3 on LISATA THERAPEUTICS, INC.
09/16/2022 3 Ruoslahti Erkki (Director) has filed a Form 3 on LISATA THERAPEUTICS, INC.
09/16/2022 3 HENSON HEIDI (Director) has filed a Form 3 on LISATA THERAPEUTICS, INC.
09/16/2022 4 AZAB MOHAMMAD (Director) has filed a Form 4 on LISATA THERAPEUTICS, INC.
Txns: Granted 19,200 shares @ $6.25, valued at $120k
09/16/2022 3 AZAB MOHAMMAD (Director) has filed a Form 3 on LISATA THERAPEUTICS, INC.
09/15/2022 8-K Appointed a new director
Docs: "Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation",
"Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation",
"WITNESSETH:",
"INDEMNIFICATION AGREEMENT",
"BASKING RIDGE, NJ and SAN DIEGO, CA",
"Lisata Therapeutics, Inc. Corporate Presentation, September 15, 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy